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Abstract 
Topoisomerase II has an essential role in maintaining the DNA in the correct topological 
state required for various cell ular processes. Its mechanism of action involves the 
introduction of a double-stranded break into the D A, passage of a different piece of 
D A through the break, followed by the religation of the D A. Topoisomerase II, in 
humans, exists as two different isofo1ms: topoisomerase II alpha, which is cell cycle-
regulated and highly expressed in rapidly proliferating cells, and topoisomerase II beta, 
which is ubiquitously expressed and it is not under the influence of the cell cycle. 
Several chemotherapeutic drugs have been designed to interfere with the catalytic 
mechanism of the topoisomerase II enzyme. By either stabilising the DNA cleavage 
complex or interfering with another step of the mechanism, these topoisomerase II 
targeted drugs promote the entry of the cell into cell death pathways. An increasing 
problem in the treatment of cancer with these drugs is the rising number of patients with 
inherited or developed drug-resistance. It has been shown that drug-resistance, at least in 
part, results from the down-regulation of topoisomerase II expression. 
The expression of a gene is a highly regulated process and the initiation of transcription 
represents a major point of regulation. Prior to this study little was known regarding the 
regulation of transcription of topoisomerase [[ beta . Understanding the processes 
surrounding the regulation of this enzyme would provide some insight as to how it is 
down regulated in drug-resistance. 
The focus of this study was to examine the role of three elements in the topoisomerase II 
beta promoter, GC I, I CB 1, and ICB2 and the transcription factors that bind to them. 
Electrophoretic mobility shifts assays revealed that Spl , Sp3 , NF-Y and two 
uncharacterised proteins are capable of binding to the promoter in vitro. Transient 
transfection assays showed in vivo that Sp I was able to activate transcription and that Sp3 
inhibited transcription driven by the topoisomerase II beta promoter. In addition the key 
activating elements appear to be ICB2 and GC l, while ICB l is inhibitory. 
- 11 -
Abbreviations 
In addition to the chemical symbols from the Periodic Table of Elements and the 
[nternational System of Units (S I) , the following abbreviations are used: 
Amp 
Ap-2 
ATF 
ATP 
ATPase 
B-gal 
bp 
BSA 
cAMP 
CAT 
cDNA 
c/EBP 
ChlP 
CMV 
CTF F-1 
DEAE 
DMSO 
dNTP 
E.coli 
E DTA 
EMSA 
FCS 
GCN5 
GFP 
Ampicillin 
Activator Protein 2 
Activating transcription factor 
Adenosine triphosphate 
Adenosine triphosphotase 
~-galactosidase 
Base pairs of D A 
Bovine serum albumin 
cyclic adenosine monophosphate 
Chloramphenicol acetyltransferase 
Synthetic D A, generated from mR A 
CCAA T/enhancer binding protein 
Chromatin immunoprecipitation assay 
Cytomegalovirus 
CCAA T transcription factor 
Diethylaminoethyl 
Dimethyl sulfoxide 
Deoxynucleoside triphosphate (dCTP, dGTP, dTTP, dATP) 
Escherichia coli 
Ethylene diamine tetra-acetic acid 
Electrophoretic mobili ty shift assay 
Fetal calf serum 
a histone acetyltransferase 
Green fluorescent protein 
-Ill-
G-segment 
G(0)-phase 
G( I )-phase 
HAT 
HDAC 
HeLa 
ICB 
ICBP90 
kb 
kDa 
LB 
MCS 
MDR 
Gated segment of D A 
Resting phase of the cell cycle 
Resting phase of the cell cycle 
Histone acetyltransferase 
Histone deactyltransferase 
Human cervical carcinoma cells 
Inverted CCAA T box 
Inverted CCAA T box binding protein of molecular weight 90 kDa 
kilobases of D A 
kiloDalton 
Luria Bertani bacteriological media 
Multiple cloning site 
Multidrug resistance 
MDR I Multidrug resistance gene 
MHC 
M-phase 
mt 
EB 
F-Y 
Major histocompatibility complex 
Mitotic phase of the cell cycle 
mutant 
New England Biolabs 
Nuclear factor Y 
NPR-A Natriuretic peptide receptor A 
ODF 
0 PG 
PAGE 
pBS 
PBS 
PBSE 
PCR 
Osteoclast differentiation factor 
o-N i trophenol ~-D-Galacto-pyranoside 
Polyacrylamide gel electrophoresis 
plasmid BlueScript 
Phosphate buffered saline 
Phosphate buffered saline with EDT A 
Polymerase chain reaction 
-IV-
pGL3Basic 
PP! 
p/CAF 
rpm 
sH20 
siR A 
S-phase 
Sp! 
Sp3 
STET 
SUMO 
T-segment 
TAE 
TAFs 
TATA 
TBE 
TBP 
TE 
TEMED 
TE 
TFIID 
TF 
TIMP-2 
TMTC 
TsAP 
XK469 
UV 
pGL3Basic vector 
Protein phosphatase I 
a histone acetyltransferase 
revolutions per minute 
sterile water 
small interfering RNA 
DNA synthesis phase of the cell cycle 
Specificity protein I 
Specificity protein 3 
Sucrose, Tris, EDTA, and triton-X buffer 
Small ubiquitin-like modification 
Transport segment of DNA 
Tris acetate EDT A buffer 
TBP associated factors 
TATA box 
Tris borate EDT A 
TATA binding protein 
Tris EDTA buffer 
,N, ',N'-Tetramethylethylenediamine 
Tris EDTA buffer with sodium 
Transcripiton initiation factor complex containing TBP and T AFs 
Transcription factor 
Tissue inhibitor of metalloproteinases-2 
Too many to count 
Thennosensitive alkaline phosphatase 
Topoisomerase II beta poison 
Ultra-violet light 
-v-
wt wild type 
3C assay Chromosome conformation capture assays 
-VI -
List of Figures 
Figure 1. 1: Schematic Representation of Topoisomerase II. .............. .......................... .4 
Figure 1.2: Mechanism of action for Topoisomerase II .. ........ ... ...... ........ ... ..... ..... .. .. ... . 6 
Figure 1.3 : Schematic Representation of the Pre-initiation Complex . .. ...................... I I 
Figure 1.4: Topoisomerase II Beta Promoter. ..... ........ ........ ... ........ ....... .. .. .... ..... .. ........ 13 
Figure 3.1: Schematic Representation of an Electrophoretic Mobility Shift Assay .... 47 
Figure 3.2: Oligonucleotide Purification .......................... ........... ...... ..... .. ... ... ... ... ....... 50 
Figure 3.3: GC I, GC2, ICB I and ICB2 Extract Titrations .. ... .. ..... ... .... ... ......... ........ ... 51 
Figure 3.4: GCI /ICB2 Extract Titration .... ...... ............... ...... ....... .. ....... ......... .... ..... ..... 53 
Figure 3.5: GCl and GC2 Antibody Supershift Assay ...... .... .. .... ..... .. ............... ... ....... 55 
Figure 3.6: ICB I and 1CB2 Antibody Supershift Assay .. ...... .. ..... ...... ..... .. .......... ...... .. 57 
Figure 3. 7: GC l/lCB2 Antibody Supershift Assay .................. ... ................................ 59 
Figure 3 .8: GC I Competitor Assay ..................... ........................................................ 62 
Figure 3.9: GC2 Competitor Assay ........ ... .. ..... ... ...... .. ... ............................................. 64 
Figure 3.10: ICB I Competitor Assay .......... .. .. .... ...... ..... .. ............. ... ....................... .... 65 
Figure 3. 11 : ICB2 Competitor Assay .................................................. ........................ 68 
Figure 3. 12 : GCI /IC B2 Double Element Competitor Assay ....................................... 69 
Figure 4.1: Schemati c Representation of PCR Mutagenesis Procedure .. ..... ... .. .... ..... 74 
Figure 4.2 : Agarose Gel of the First Round PCR Mutagenesis Products ... ................ 78 
Figure 4.3 : Agarose Gel of the Second Round PCR Mutagenesis Products ... ........ 8 1 
Figure 4.4: Schematic Representation of Cloning Strategy ......................... ...... ..... .... 82 
Figure 4.5: Agarose Gel of a Diagnostic Digest. ..... .. ...... ...... ....... .............................. 87 
Figure 4.6a: Sequencing Results for Mutant Constructs .................... ... ..... ................ 88 
Figure 4.6b : Sequencing Results for Mutant Constructs ... .. ... .................................... 89 
Figure 5. 1: Reaction Cata lysed by Firefly Luciferase ......... ..... .. ... .. ...... .. ........ .......... .. 93 
Figure 5.2: Reaction Cata lysed by P-Galactosidase ............ ................... ....... .... .......... 94 
Figure 5.3: Standard Deviation Fonnula .. ... ............... ... .. ............... .. ..... ................ ...... 97 
Figure 5.4: Two Sample t-test Formula . ........ ....... ........... .. ... .... ........... .... .. ...... .... ... ... .. 98 
Figure 5.5 : Agarose Gel of the Diagnostic Digests .... .. ... ... ..... .. ... ........ ...... .... ........ ... 102 
Figure 5.6: Schematic Representation of a Transient Transfection using a Co-
expression Vector. .. ..... ... .......... .. ........ ... ... ........ ..... ...... ... ... .. .. ... ... ... .................... .. .. ... . 105 
Figure 5.7: Effect of Spl on - 1357 bp Topoisomerase II Beta Promoter Construct.107 
- Vll -
Figure 5.8: Effect of Sp l on - 654 bp Topoisomerase II Beta Promoter Construct. .. 110 
Figure 5.9: Effect of ~-galactosidase on Relative Luciferase Activities . .. .... .......... . 112 
Figure 5.10: Effect of Sp3 on - 1357 bp Topoisomerase II Beta Promoter Construct. 
.. ......... .. .. .......... .. .... .. ...... .. .. ...... ..... ........ .. ... .. ... ..... ......... ..... .. ..... ....... .... .. .. ...... ... .. ... ..... 113 
Figure 5.11: Effect of Sp3 on - 654 bp Topoisomerase II Beta Promoter Construct. 115 
Figure 5. 12: Effect of Mutations on Topoisomerase II Beta Expression . .... ....... .... .. 119 
Figure 6. 1: Schematic Representation of Two Purification Procedures . ...... ........ ... . 127 
Figure 6.2: Schematic Representation of a Chromosome Capture Conformation 
Assay . .. ...... .... ..... .... .... ... ... ..... ...... ..... .. .... .... .. ... ... .... ... ...... .... ... ............ ..... ........ ..... .. .... 129 
-Vlll-
List of Tables 
Table 3.1 : Extract Titration Results .. ................. .... ........... ..... ...... ......... ..... ... .......... ..... ..... 52 
Table 4.1 : Standard First Round PCR Mutagenesis Reactions .... ........... .................... ...... 76 
Table 4.2: PCR Conditions ......... ...... ........... ....... .... ...... .... .... ....... .. .. .......... ........ ....... ....... .. 77 
Table 4 .3: Expected Products for First and Second Round of PCR Mutagenesis .. ...... ..... 78 
Table 4.4: Standard Second Round PCR Mutagenesis Reactions .... ... .... ..... .......... ... ....... . 80 
Table 4.5: Standard Ligation Reactions ............ .. .... ..... ...... ... .. ... .. ... ... ............. .... .............. . 83 
Table 4.6 : Standard Transfonnation Reactions .... .... ... .. ... ... ......... ........... ..... ... .. ......... ... .... 84 
Table 5.1 : Transient Transfection Calculations ............... .......... ...... ..... ... .. ....... ................. 96 
Table 5.2: p-values and Their Significance ........ ...................... ... ....... .... .. ... ... .. ... ... ........... 99 
Table 5.3: Diagnostic Digest Reactions and the Expected Product Sizes . .... .. ..... ........... I 00 
Table 5.4: Quantities of Plasmid DNA used for Sp I Co-expression Transient 
Transfections with the - 1357 bp Topoisomerase II Beta Promoter Construct. ... ...... .. .... 106 
Table 5.5: Quantities of plasmid DNA used for Sp I Co-expression Transient 
Transfections with the - 654 bp Topoi somerase II beta Promoter Construct. ................. I 09 
Table 5.6: Quantities of plasmid DNA used for Topoisomerase II Beta Mutant Promoter 
Construct Transient Transfections . ... ...... .. .. ... .... ... ... ..... ...... .. .... .... ... .. .... .............. .. ..... .. ... I 17 
-IX -
Table of Contents 
ACKNOWLEDGMENTS ................................................................................................. I 
ABSTRACT ........................................................................................... ............................ 11 
ABBREVIATIONS ............................................................................... .......................... Ill 
LIST OF FIGURES ....... ................................................................................................ VII 
LIST OF TABLES .......................................................................................................... IX 
LIST OF TABLES .......................................................................................................... IX 
TABLE OF CONTENTS ................................................................................................. X 
TABLE OF CONTENTS ................................................................................................. X 
1. INTRODUCTION ...................................................................................................... 1 
I . I . O VERVIEW ........ ........................... ................ ................ ............ ............ .... ... .... ..... 1 
1.2. T OPOISOMERASES .............. .... ........ ... .. ....... ...................................................... .. .. 3 
1.3. T OPOISOMERASE ( [ ASA CHEMOTHERAPY TARGET .............................................. 6 
1.4. TRANSCRIPTION I EUKARYOTES ........... ............ ...... ... ......... .. ............... ..... ........ 10 
1.5. TOPOISOMERASE II BETA .............................. ......................................... ..... ....... 12 
I. 5.1. The Topoiso111erase 11 Beta Promoter ..... ...................................................... 12 
1.5.2. CCAA T Boxes .. .... ..... ......... .. .... ......... .. .................. ................. ......... ........... ... 13 
1.5.3. NF-Y ... ... ... .... ....... ............... .......... ... ................. ........ .. ... .. .. ... ....... .......... .... .... 15 
1.5.4. GC-rich Elements ........................ .... .......... .. .. ..... ........ .. ...... .... ....... ...... .. ....... 17 
1.5.5. Sp Family a/Transcription Factors .......... .. ... .. .. ...... ................. ............ ....... . 18 
1. 5.6. Sp / ......... .. ... ........................................... ................ .... .... ... ..... ... ... ...... ... ...... .. 19 
1.5. 7. Sp-I and NF-Y Interactions ... ......... ...... ... ........ ...... .. ..... ..... ......................... .. 20 
1.5.8. Sp3 ...... ... .. .. .......... .. ........ .... .... .... .. ....... .... ...... ......... .... ............. .............. ... ..... 21 
1.6. PROJECT O UTLI E ····· ·· ··· ·· ·· ··· ·· ··· ······· ··· ····· ·· ·· ················· ············· ·······················23 
2. MATERIALS AND METHODS ............................................................................. 26 
2. 1. M ATERIALS ................... ........... ......... .. ... .... .. .. ...... .. ... ...... .. ... .. .... ........ ..... ......... .. 26 
2.2. M ETH0 DS .... ........................................... ........ ................ ......... ...... ......... .... ... .... . 29 
2. 2. 1. Agarose Gel Electrophoresis .. ... ............................... .... ... .... .. ... ....... .... ......... 29 
2.2.2. Restriction Endonuclease Digests ............. ..... ................... ............................ 29 
2.2.3. Removal of 5 ' Phosphate Groups ..... ......... ..... .. ....... .... .. .... .. .... .. ......... ........ ... 30 
2.2.4. DNA Purification using the Freeze-Squeeze Method .. ... .. .... ........... ........ ... .. 30 
-x-
2. 2. 5. Ethanol Precipitation .. ... ... .... ..... .......... ............................. .. .... ...................... 31 
2.2.6. O/igon ucleotides ... ... ... .. .... ..... .... ............ .. .... .. .... .. ... .... .. .. ... ....... .. ... ... ... .... ..... 31 
2.2. 7. Polymerase Chain Reaction .... ... ... .............. ....... .. .... ... .......... ... ... ...... ... .. ....... 32 
2.2.8. Ligation Reactions .................. ... ...................... .......................... .......... ... ... ... 32 
2. 2. 9. Transformation of Escherichia coli XL-I Cells ....... ... .............. ....... ...... ... ... . 33 
2.2 .9.1 . Grow on the Day Competent Cells ....................................... ........... 33 
2.2. 9. I . I . Preparation of Competent Ce l Is .. ........... .... ....... ... ... ............ ............. 33 
2.2.9. 1.2. Transfonnation Procedure ........... ..... ................. ................... ... ......... 33 
2.2.9.2. Calcium Chloride Competent Cells .. ....... .. ....................... .. ............. 34 
2.2.9.2. 1. Preparation of Competent Cells ..... .. ................ .................. ... ... ... ..... 34 
2.2 .9.2.2. Transfom1ation Procedure ..... .. .............. ................. ........ ........ .. .. ...... 34 
2.2. 10. Plasmid Preparations ........... ......... ................ ........ .. .. ....... ........................ 35 
2.2.10.1. Rapid Boil Plasmid Purification ...................... ..... ............................. 35 
2.2.10.2. MiniPrep Plasmid Purification .... ... ..... .. ... .. ...... ... ...... .. .... .... ........ ...... 35 
2.2.10.3. MaxiPrep Plasmid Purification ...... ..... .... ......... .. .... .. ........... .............. 36 
2.2. 11 . DNA Quant(fication .......................... .. ......... .. .. .. ... .................................... 36 
2.2.11.1 . Quantification using Gel Electrophoresis ............. .. ....... .. ..... ...... .... 36 
2.2.11 .2. Quantification using UV Spectrophotometry ... ...... ........ .............. ... 37 
2.2.1 2. Sequencing of DNA .................... ........ .. .................... ... ............. .. ..... .... .... .. 3 7 
2.2. 13. Electrop/10retic Mobility Shi/i Assays ..... ........ ...... ... .... ..... .... ... .... ... ......... 38 
2.2.13.1. Oligonucleotide Labelling ......... ....... ...... ............ ......... ..... ..... ... .... ..... 38 
2.2.13.2. Purification of the labelled oligonucleotide ............. ........................ 38 
2.2.13.3. Preparing Double Stranded Competitor Ol igonucleotides .......... 39 
2.2.13.4 . Electrophoretic Mobility Shift Assays ................................... ..... .... .. 39 
2.2. 14. Tissue Culture .... .......... .... ... ... ... ..... ... .. ..... ......... .... .... ... .... ........... ..... .. .. ..... 40 
2.2.14.1 . Growing Hela Cells ....... ..................... ...... ... ................... .. .. ...... ..... .... 40 
2.2.14.2. Maintenance of Hela Cells ...... ........ .... ............. .... .. ....... ...... .... ....... .40 
2.2.14.3. Freezing Hela Cells ........... ....... .. ...... ....... ... ... ... ....... ...... .......... ... ..... .4 1 
2. 2. 1 5. Preparing He La Whole Cell Extracts ... .. ...... ... .... .. .. ....... .. ........... .. ........... 4 1 
2.2. 16. Bradford Protein Assays ... .... .. ........ ... .. ............................................. ..... ... 41 
2.2. 17. Transient Tramfections .. ..... ....................... .................... .......... ......... ... .... 42 
2.2. 18. Harvesting Cells ..... ... ... ... .... .................................................. .. ...... ......... .. 42 
2.2.18.1. ~-galactosidase assays .. ... .................................................... ........ ... .42 
2.2.18.2. Luciferase Assays .................... .... .. ....... ... .................... ......... ............ .43 
2.2. 19. GMO Approval Codes ....................... ..... ........ ..... .... ............... ..... .. .......... . 43 
-XI-
3. ELECTROPHORETIC MOBILITY SHIFT ASSAYS ......................................... 45 
3. 1. l NTRODUCTION ......... .. .. ... ..... ............ .... ......... .......... .. .. ... ....... .. ............ .... ........... 45 
3.2 . BIND! G OF PROTEI S TO T HE T OPOISOMERASE II B ETA PROMOTER .................. 48 
3. 2.1. He La Protein Extract Preparations .............................................................. 48 
3.2. 2. Oligonucleotide Preparation ...................................... ..... .... ... .. .. .. ... ...... .. ..... 49 
3.2.3. Extract Titratio11s .. .... .. ... .. ............ ........ .. .... ... ......... .... ................... ... ............. 50 
3.2.3.1. Single Element Extract Titrations .. .......... ...... .. ...... .. ................ ...... .. 50 
3.2.3.2. Double Element Extract Titrations .................... .. ......... .... ................ 52 
3.2.4. Antibody Supershift Assays ........ .... .. ..... .. .... .. .... .... .. ..... .. ........ .... ........ .. ......... 54 
3.2. 5. Competitor Assays .................... .. ................. ............... ......... ............... .......... 60 
3.3. CHAPTER SUMMARY ........... ... ... .. .................. ................ .. ................................... 70 
4. CLONING OF THE TOPOISOMERASE II BETA PROMOTER ..................... 72 
4. I. I TRODUCTION ........................................ .. ...... . ................................. . ...... ...... .... 72 
4.2. PC R M UTAGENESIS .......... ... ..... ............... ........ .. ... ......... .. ....... .. ......................... 73 
4.2. I . First Round PCR Mutagenesis .. .. ............................................................ ...... 75 
4.2.2. 
4.:l.3. 
4.2.4. 
4.2.5. 
4.2.6. 
4.2.7. 
4.3. 
Second Round PCR M11tage11esis ... ... ........... ........... ... .. ... ....... ....... .... ... ......... 79 
Digestion and Removal o/'5' Phosphate Croup ..................................... ....... 81 
Ligations ... ............................................. ..... ...... .... .... .................... .... ...... .... .. 83 
Tra11sformatio11s ......... ....... ... ................. ............ ........ ... .... .......... ......... .. ........ 83 
Screening for Mutants ......................... .......................................................... 86 
Sequencing ......... .................................................. ....... .......... ........................ 87 
SUMMARY ......... ...................................................... ................... ..... .......... ......... 90 
5. TRANSIENT TRANSFECTIONS ......................................................................... 91 
5.1. I NTRODUCTION .... . ..................... .... ..... .. .... ...... .... .......... .... ...... ...... .. ............ .. ...... 9 1 
5. 1.1. Luciferase Assays ............................... .. ................................ .......... .. ............ . 92 
5. 1.2. (JCalactosidase Assays .. .. ................ ....... .... ......... .. ............ .......................... 94 
5. 1.3. Analysis of Results ...... ................................................. .... ............... .. .. ..... ..... 95 
5.2. PLASM ID PREPARATIO .. .... ...... .......... .... ...... ...... .. ........ .. .......... ........ .... .. .. ........ 100 
5.3. TRANSIENT T RA SFECTION I H ELA CELLS ..................................................... I 03 
5.3. I . Sp/ Co-Expression Transfections ...... .. ... ... .. ..... .. .. .... ...... ...... ................ ...... 103 
5.3.2. Sp3 Co-Expression Transfections .. ........................................................ .. .. . 11 l 
5.3.3. Transient Transfection using the Mutant -654 Topoisomerase II Beta 
Promoter Constructs ....................... ................. ....................................................... 116 
-Xll-
5.4. SUMMARY ................. . ..... ...... ................... ........ ................. ........... ......... ........... 120 
6. SUMMARY AND FUTURE DIRECTIONS ........................................................ 121 
6. 1. ELECTROPHORETIC M OBILITY SHIFT ASSAYS .................................. .. ............... 121 
6.2. T RA1 SIENT T RANSFECTIONS ... ... ........................................ ......... .. .. ................. 122 
6.3. FUTURE DI RECTIO S .............. .......................................... .. ..... ........ . ................ 123 
6.3. 1. Transcription Factor Binding Assays ................... ...................................... 123 
6.3.2. Cloning and Transient Transfections ................ ................ ................ .. ........ 124 
6.3.3. Characterisation of the Un identified Proteins .. ...... ... ...... ...... .... ..... .. .. .. .. .. .. 125 
6.3.4. Chromosome Conformation Capture Assays .............. .. ... .................... .. ..... 128 
6.3.5. investigation of Topoisomerase fl alpha and Topoisomerase 11 beta .. ...... 130 
6.4. CONCLUSION ............................................. .. ...... ...... .................. ...... ................. 132 
REFERENCES .............................................................................................................. 134 
APPE DIX ..................................................................................................................... 147 
APPENDIX 1: PRIMER AND OLIGONUCLEOTIDE SEQUENCES ................... 147 
APPENDIX 2: PROTEIN STANDARD CURVE ...................................................... 149 
APPENDIX 3: VECTOR MAPS ................................................................................. 150 
APPENDIX 4: TOPOISOMERASE II BETA SEQUENCES ................................. 151 
APPENDIX 5: TRANSIENT TRANSFECTION DATA ........................................... 159 
-XIII-
Chapter 1 - Introduction 
1. Introduction 
1.1. Overview 
Topoisomerases constitute a family of highly conserved nuclear enzymes, which have 
been found to exist in all investigated living prokaryotic and eukaryotic cells. By 
introducing transient single- or double-stranded breaks in DNA, topoisomerases can 
reduce the torsional strain placed on DNA, and thereby allow D A to exist in the correct 
topological form required for many different cellular processes. There are three classes of 
topoisomerases (1, II , and rII) of which topoisomerase II is the only one essential for 
viability in eukaryotes. Topoisomerase II is divided into two isoforms: alpha and beta. 
Mammalian topoisomerase II alpha expression is cell cycle-dependent and it is highly 
expressed in rapidly proliferating cells. Expression of topoisomerase II beta is not cell 
cycle-regulated, and it is expressed at similar levels in all cell types except in tumours 
where it may be up-regulated . 
The two isofonns of topoi somerase II are important chemotherapy targets . 
Topoisomerase poisons stabilise the cleavage complex formed between the topoisomerase 
II and DNA, and this drug-induced D A damage sends the cell into apoptotic pathways . 
Catalytic inhibitors however, work by inhibiting other steps of the topoisomerase [l 
catalytic cycle. Increased levels of topoisomerase II alpha convey a greater sensitivity to 
chemotherapy; decreased levels lead to drug-resistance. Both the alpha and beta isoforms 
have been shown to be down-regulated in drug-resistant cell lines, however, the 
mechanisms involved remain largely unknown. It is possible that this down-regulation is 
caused by changes in mR A stability (Goswami et al. , 1996), post-translational 
modifications of the enzyme (Burden and Sullivan, 1994), or transcriptional regulation 
(Isaacs et al. , 1998) . 
Marked differences in biochemical properties, nuclear localisation, and expression 
profiles suggest that the ce llular ro le of topoisomerase II alpha and beta are very different. 
A large number of studies have been carried out to detennine the mechanisms involved in 
the transcriptional regulation of topoisomerase [l alpha, in order to explain its expression 
pattern and down-regulation associated with drug-resistance (Isaacs et al., 1996; Magan 
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et al. , 2003; Allen et al., 2004) . Many of the transcription factors, which bind to the 
promoter, have been reported and functionally analysed with respect to their effects on 
expression of repo11er genes driven by regions of the topoisomerase II alpha promoter 
(Magan, 2002; Magan et al. , 2003) . Three previous studies have provided some insight 
into the mechanisms involved in the transcriptional regulation of topoisomerase II beta 
(Ng et al., 1997; Lok et al., 2002; Willingham, 2004), nevertheless these remain poorly 
characterised. The ai m of this study was to identify transcription factors that bind to the 
topoisomerase II beta promoter, and to functionally characterise some of the observed 
interactions, as a means to understand the mechanism respon sible for the down-regulation 
of topoisomerase I I beta associated with drng-resistance. 
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1.2. Topoisomerases 
Topoisomerases are a class of nuclear enzymes, which catalyse the interconversion of 
topologica l isomers of DNA. They relax supercoiled DNA, thereby relieving the 
torsional strain placed upon the DNA during common cellular processes such as 
replication, transcription, chromatin remodelling, and recombination . They also play a 
major role in the decatenation and unknotting of DNA (S hiozak i and Yanagida, 1991 ). 
The mechanism of action for all topoisomerases involves the cleavage of the D A 
phosphate ester backbone, followed by the formation of a covalent phosphotyrosyl link 
between the enzyme and the D A. After the formation of the protein-D A intennediate, 
a sing le- or double-stranded D A segment passes through the break, and religation 
occurs once the correct D A conformation is achieved (reviewed in Roca, 1995). 
There are three different types of topoisomerases in higher eukaryotes: type r, rI , and Ill . 
Topoisomerase I works to correct both overwound and underwound duplexes by 
introducing a single-stranded break in DNA . This enzyme does not require ATP, or a 
meta l ion as a co-substrate. Topoisomerase I plays an important role in relaxing 
supercoil s generated during transcription , and it is indispensable during development (Lee 
eta/., 1993 ; Morham eta!., 1996). 
Topoisomerase m general ly catalyses the relaxation of underwound D A. It only 
relaxes overwound DNA if there is a pre-existing break in the DNA. The mechanism of 
action is fundamentally different to other classes of topoisomerases, and involves the 
unpairing of double-stranded D A before a break is introduced into a si ngle-strand 
(Wang, 1997). There are two isofonns of topoisomerase m, the alpha and beta isofonns. 
Topoisomerase III alpha is required during embryogenesis (Li and Wang, 1998), and 
topoisomerase III beta may play an important role in the resolution of double-Holliday 
junctions (Kwan et al. , 2003). 
Topoisomerase II is an essential nuclear enzyme. These enzymes introduce a staggered 
double-stranded break into the D A, which allows the passage of the intact double-
stranded D A through the break. This process requires ATP to catalyse the resetting of 
the enzyme before it can undertake a second round of catalysis. Topoisomerase II is 
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capable of relaxing both overwound and underwound D A, decatenation , and unknotting 
of DNA. 
Shiozaki and Yanagida ( 1991) determined the basic structure of yeast topoisomerase I 1. 
These authors found that the protein exists as a homodimer and that each subunit consists 
of three functional domains: an N-terminal A TPase domain, a central DNA breakage-
rejoining domain containing the active site tyrosine residue, and a C-terminal domain 
required for nuclear localization (Figure 1.1 ). The C-terminal domain however, is not 
essential for catalytic activity. 
Figure I. l: Schematic Representation of Topoisomerase 11. 
Topoisomerase II is a homodimeric enLyme and each half has an ATPase domain (Yellow ). a DNA 
breakage-rejoining domain (Red) and a nuclear localiLati on domain (Blue). Figure from Berger el al. 
( 1996). 
Berger et al. ( 1996) uncovered the general mechanism of action of topoisomerase 11 and 
since then it has been widely accepted as the model for topoisomerase II action (Figure 
1.2). Topoisomerase If binds to a double-stranded segment of D A (G-segment) , and 
upon binding a confonnational change in the enzyme occurs. A second segment of D A 
(T-segment) is brought into the enzyme, and at the same time ATP binds to the A TPa e 
domains . The enzyme then undergoes a series of conformational changes in which the 
enzyme closes up around the DNA strands. The cleavage process of the G-segment 
involves transesterification between two active site tyrosine residues (one in each half of 
this dimeric enzyme) and two DNA phosphate ester bonds four base pairs apa11 in the G-
segment. The oxygens from the tyrosine residues covalently bind to the 5' phosphoryl 
groups of the broken D A and the broken ends move away from each other. 
Concomitant with this process is the dimerisation of the A TPase domains. Next, the T-
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segment is transported through the broken DNA and into the center of the enzyme. Once 
the T-segment has been passed through, a second transesterification occurs between the 3' 
hydroxyl group and the phosphotyrosyl bond. This transesterification step leads to 
rel igation of the DNA, and following this the T-segment is released through a second gate 
in the enzyme. ATP is then hydrolysed, and the enzyme undergoes a further 
conformational change, which returns it back into the starting state. The G-segment is 
either released or the process starts over again. 
Topoisomerase II exists as two isofonns. Chung et al. ( 1989b) sequenced several partial 
topoisomerase II cD A clones obtained from a human cD A library, and found two 
classes of nucleotide sequences. One was identical to that of a previously sequenced 
cDNA, topoisomerase IL alpha, and the other encoded a slightly larger protein, 
topoisomerase II beta. 
Topoisomerase II alpha is encoded on human chromosome I 7q2 l-22 (Tan et al. , 1992), 
and the protein is 170 kDa in size (Chung et al. , 1989b). Its expression level s vary 
throughout the different stages of the cell cycle, therefore it is speculated to have a role in 
cell cycle-regulation. It is expressed at low levels in quiescent cells, and at high levels in 
proliferating cells (Hsiang et al., 1988) and therefore, topoisomerase 11 alpha is highly 
expressed in rapidly growing tissues, such as the spleen and the thymus (Tsutsui et al. , 
1993). 
The topoisomerase II beta gene resides on human chromosome 3p24 (Tan et al., 1992), 
and it is slightly larger than the alpha isofonn, 180 kDa in size (Chung et al., 1989b ). The 
cellular role of topoisomerase II beta is not fully understood, and its regulatory 
mechanisms are sti 11 under investigation. Topoisomerase [I beta 1s expressed 
independently of cell cycle and growth status (Kimura et al., 1994), localized mostly in 
the nucleolus (Woessner et al., 1991 ), and it is expressed at similar levels in all tissues 
(Tsutsui et al. , 1993 ). 
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Figure l.2: Mechanism of action for Topoisomerase II. 
Topoisomerase II binds to doub le-stranded DNA. the Gate segmen t (G-segment). and a conformation change 
occurs in the enLyme (2). Si multaneously AT P binds. and the Transpo rt DNA (T-segmen t) moves into the 
enzy me (3 ). The A T Pase domains clamp shut. and the G-segment is c leaved ( 4 ). The T-segment moves 
through the cleaved G-segment , and is re leased from th e enzy me. ATP is hydro lysed. and the G-segment is 
religated (5) . T hrough a conformationa l change, topo isomerase II retu rns to its start ing state, and the G -
segment is e ither released or the proce s sta rts again (Be rger et al. , 1996). 
1.3. Topoisomerase II as a Chemotherapy Target 
The firs t anti-cancer drugs that were designed and effective in treating cancer had no 
known cel lular target. After approximately 20 years of use and a large amount of 
experimental work topoi somerases were show n to be a key intracellular target for these 
drugs (Ross et al., 1978 ; Ross et al., 1979). Topoisomerase II makes an ideal drug ta rget, 
as it is an essentia l enzyme, whic h lacks functi onal redundancy w ithin the cell. 
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The drngs that target topoisomerases can be divided into two classes: poisons and 
catalytic inhibitors. Topoisomerase poisons act by stabilising the DNA-topoisomerase 
cleavage complex, thus preventing the religation of the DNA. The double-stranded 
breaks in the D A are recognised by the caspases, which then lead the cell into 
programmed cell death (Benjamin et al., 1998). Topoisomerase inhibitors, interfere with 
the catalytic function of the enzyme without stabi li sing the DNA-topoisomerase cleavage 
complex . They may act either by preventing the topoisomerase enzyme from binding to 
the D A, or by locking the D A bound topoisomerase in the shape of a closed clamp. 
Topoisomerase II alpha is the target of many anti-cancer drugs because of its increased 
expression in rapidly proliferating cells. Qiu et al. ( 1996) provided evidence that the anti-
cancer drug etoposide (classified as an epipodophyllotox in) was capable of stab ilizing the 
topoisomerase II alpha-DNA cleavage complex. This D A damage, which would cause 
a halt in transcription , is likely to be sensed by the cell , leading the cell into cell death 
pathways. 
While topoisomerase II beta is expressed at lower level s in the cell (compared to 
topoisomerase II alpha) it does not mean it is less important in the treatment of cancer. 
Several studies have shown that some topoisomerase II poisons work by acting on 
topoisomerase II beta as well as the alpha form (EITington et al., 1999) and that some 
selectively target this particular isoform (Gao et al. , 1999). Topoisomerase II beta may 
provide an ideal target in the treatment of solid tumours. Solid tumours are slow growing 
and therefore do not have an increased level of topoisomerase II alpha like the highly 
proliferating cells found in leukemias for example. Gao et al. ( 1999) reported the 
discovery of the topoisomerase II beta poison XK469 ( classified as a quinoxaline 
phenoxypropionic acid derivative) that is effective in the treatment of solid tumours. 
They also reported that XK469 could be a n alternative treatment for those cancers, wh ich 
show multidrng resistance. 
Drug-resis tance is a major clinical problem when treating tumours with chemotherapeutic 
drugs. This resistance can either be inherited or acquired when repeatedly exposed to the 
drugs. Resistance occurs not only to the drug being used but also to a group of 
structura lly unrelated compounds giving the multidrug resistance phenotype. An increase 
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m expression of the Pl70 glycoprotein (Grimaz et al., 1998) or decreases m the 
sensitivity of topoisomerase II have both been implicated in this phenomenon. 
Topoisomerase II alpha and beta expression is regulated in a number of ways. mR A 
stab ility has been implicated to have a role in the regulation of topoisomerase II alpha 
(Goswami et al. , 1996). These authors showed that topoi somerase II alpha mRNA has 
the greatest stability during S-phase with a half life of 4 hours and the shortest half life 
during G( I )-phase of only 30 minutes . This correlates to the observed cell cycle-
expression of topoisomerase II alpha. Topoisomerase II alpha and beta are also subject to 
phosphorylation) the levels of which are greatest at M-phase (Burden and Sullivan, 
1994). Neither of these observations explains the down-regulation of topoisomerase II in 
many cell lines and tumours. Several studies have shown that this down-regulation has 
been due to a decrease in mRNA resulting from decreased transcriptional activ ity and not 
through mRN A stabi I ity (Kubo et al., 1995 ; Asano et al., 1996; lsaacs et al., 1998). 
Topoisomerase ll alpha levels were measured in a human stomach-adenocarcinoma cell 
line either sensit ive or resistant to adriamyc in (Son et al. , 1998). Western blot analys is 
showed that in drug-res istant cells there was approximately a 20-fold decrease in 
topoisomerase II a lpha in comparison to drug-sensitive ce lls. Son et al. ( 1998) also 
reported when the above cells were exposed to etoposide there was a 20-fold decrease in 
the number of topoi somerase II alpha-DNA covalent complexes fonned in drug-resistant 
cells when compared to drug-sensitive cells. Another study showed that high level of 
topoisomerase II alpha were observed in rapidly proliferating tumours (Turley et al. , 
1997). 
Several mutations in the topoisomerase II alpha gene have been shown to cause a drug-
resistant phenotype . Wessel et al. ( 1999) examined a human small cell lung cancer cell 
line and found a substitution of an arginine to a glutamine (R l 62Q) in the ATP utilization 
domain, which conveyed resistance to the catalytic inhibitor ICRF-187 (classified as a 
bisdioxopiperazine). A 20-25% decrease in activity was observed for this mutation when 
compared to wild type topoisomerase II alpha. Previously, this same group had reported 
a tyrosine to phenylalanine (Y49F) substitution in a Chinese hamster ovary cell line, 
which is resistant to the topoisomerase II catalytic inhibitor ICRF-159 ( classified as a 
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bisdioxopiperazine) (Sehested et al., 1998) . This mutation, located in the N-terminal 
clamp end of the enzyme, was introduced into topoisomerase II alpha in a ICRF-159 
sensitive human cell line and resistance to ICRF-159 was subsequently observed. 
Furthennore, de Lucio et al. (2005) characterised a non-small cell lung cancer cell line in 
order to detennine the cause of the observed resistance to the topoisomerase II poison 
etoposide (characterised as an epipodophyllotoxin). Northern blot analysis revealed two 
truncated mRNA fragments of which the 4 .8 kb mRNA encoding the topoisomerase II 
alpha protein was used for subsequent analysis . Western blot analysis showed that it was 
the C-tenninal end of topoisomerase II alpha that was absent, and this is the region 
required for the cotTect cellular localisation of the protein to the nucleus . 
Immunocytochemical detection showed that the truncated topoisomerase II al pha protein 
was located in the cytoplasm and therefore non-functional. From this the authors 
concluded that the observed resistance to etoposide was due to the incorrect cytoplasmic 
locali sation of the protein and therefore it was unable to can-y out its function in the 
nucleus . 
Topoisomerase II beta expression tn acute lymphoblastic leukemia cells howed a 
correlation with cytotoxicity to doxorubicin and etoposide (Brown et al., 1995; Markovits 
et al. , 1995). Topoisomerase II beta knockout mouse cells showed that these cells were 
3-times more resi stant to XK469 than were wild type cells (S napka et al., 200 I) . Down-
regulation of topoisomerase II beta is also a cause of resistance to the topoisomerase II 
inhibitor mitoxantrone (classified as an anthracycline) in leukemia (Harker et al., 1991 ). 
Western blot ana lysis showed the topoisomerase II beta protein could no longer be 
detected in these cells, and therefore the catalytic activity was also reduced. This 
decrease in the drug target means that even though the drugs are being taken up by the 
cell there is no longer a sufficient level of target enzyme therefore they are no longer 
effective in treating the cancer. 
Padget et al. (2000) used a quantitative western blot method to investigate the relative 
levels of topoisomerase II alpha and beta in drug-sensitive and drug-resistant cells. From 
this they suggested that the relative levels of topoisomerase II alpha and beta might be 
important in detennining a tumours response to anti-cancer drugs. 
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All these studies directly implicate the level and integrity of topoisomerase I£ alpha and 
beta in the response of tumours to chemotherapy. 
1.4. Transcription in Eukaryotes 
One of the major points of regulation in the expression of a gene is at the transcriptional 
leve l, and this could have a very important role in the regulation of both topoisomerase II 
alpha and beta. Transcriptional regulation invo lves the fonnation of severa l different 
protein complexes binding to proximal and distal elements in the promoter of a gene, and 
the subsequent recruitment of RNA polymerase II. RNA polymerase II is responsible for 
transcribing the protein coding genes . 
A large number of promoters contain a TA TA box, which has a consensus sequence of 
TAT AAAA. The TAT A box is located on average 25 bases upstream of the transcription 
sta11 site, and it provides a platfonn for the assembly and positioning of the pre-initiation 
complex close to the transcription start site. TFIID, made up of the TAT A binding 
protein (TBP) and a number of TA TA associated factors (TAFs), is the first to bind to the 
TA TA box in association with TFIIA. TFIIB binds next, fo llowed by TFIIF, which in 
tum recruits RNA polymerase II. TFIIE and TFIIH bind last in the complex assembly 
(Figure 1.3) (rev iewed in Shidlovskii et al., 2005 ). This precise and orchestrated 
assembly of proteins is important to con-ectly regul ate the express ion of a gene. Often, 
however, there are other upstream elements ( other than a TA TA box) both proximal and 
distal , which are utilized to direct transcription within a promoter. 
Not all promoters contain a TA TA element and this is common in housekeeping genes 
and developmentally-regulated genes. It therefore follows, that no canonical TA TA box 
has been detected in either topoisomerase II alpha or beta. Genes that lack TAT A boxes 
rely on other elements in the promoter region to recruit the proteins required to form the 
pre-initiation complex, for example a GC-rich element or a CCAA T box. Both the 
transcription factors Spl (which binds to GC-rich elements) and F-Y (which binds to 
inverted CCAA T boxes) have been shown to interact with TAFs, and therefore, these 
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proteins may play a vital role in TAT A-less promoters through interactions with their 
respective binding sites (reviewed in Suske, 1999; Frontini et al., 2002). 
Pol llA 
.v• j,i•:~H-
Figure 1.3: Schematic Representation of the Pre-initiation Complex. 
Transc ription factor I ID (TF I ID ) is the protein complex which recogni ses the TAT A t:lt::ment in a number of 
euk aryotic promoters. TF I ID binding to a promoter starts a cascade or protein-prote in interactions. which 
recruit RN A polymerase 11 to the promoter. Figure from Nikolov and Burley ( 1997). 
One general mechanism involved in transcriptional regulation is via the acetylation state 
of the promoter. Hi stone acetyltransferases (HA Ts) bind to chromatin in the promoter 
region, and acetylate lys ine residues at the -terminal end of histones. This weakens the 
histone-DNA interactions, destabilises the nucleosomes, and results in the opening of the 
chromatin tructure. Transcription factors can then gain access to the promoter region of 
the gene, and the pre-initiation complex can assemble. Histone deacetylases (HDACs), 
which are also capable of binding at promoter regions, remove the acetyl moiety. Thi 
leads to closing of the D A structure . Through the opening and closing of the chromatin 
structure, the transcription of a gene can be regulated. 
Basal transcription can either be enhanced or repressed by proteins binding to various 
elements, which can exist upstream or downstream of the transcription start site. Each 
promoter has its own unique set of transcription factors and elements, therefore the level 
of expression of a gene is dependent on which regulatory proteins are present and 
required to bind to the promoter. 
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1.5. Topoisomerase II Beta 
A general role for topoisomerase ll beta remains evasive. A possible role for this protein 
in neural development however, has been proposed (Yang et al., 2000) . These authors 
generated topoisomerase II beta knockout mice, and found that these mice failed to 
develop appropriate neural innervat ion of skeletal muscle. In these studies the mice died 
soon after birth due to a breathing impairment, which supports this speculation. Kondapi 
et al. (2004) further examined the topoisomerase U beta protein in rat brains at various 
developmental stages. These authors found a significant age dependent decline in 
topoisomerase II beta activity in the cerebellum. From this it was suggested that the low 
levels of topoisomerase II beta activity may contribute to genomic instability in the 
ageing cerebellum. The precise function of topoisomerase II beta, however, has yet to be 
elucidated. 
1.5.1. The Topoisomerase II Beta Promoter 
g et al. ( 1997) were the first group to clone and characterise the topoisomerase II beta 
promoter. Initially , two transcription start sites were identified; one was 193 nucleotides 
and the other was 89 nucleotides upstream of the translation start codon (A TG) . Based on 
RNase protection assays the majority of transcription initiation occurred 193 nucleotides 
upstream of the translation start site, and therefore this position was designated + I ( g et 
al., 1997). 
The topoisomerase II beta promoter has a high GC content (77%) and a high frequency of 
CpG dinucleotides (Ng et al., 1997). CpG dinucleotides are suspected sites for 
methylation and could be important for transcriptional repression. Like topoisomerase ll 
alpha and other housekeeping gene , topoisomerase II beta lacks a TAT A box. 
Initial deletion assays suggested that one or more transcriptional activators may bind 
between - 1000 and - 500, and that one or more transcriptional inhibitors may bind 
between - 500 and - 14 (Ng et al., 1997) relative to the transcription start site at + I. Later 
on, more extensive studies of the 5' upstream regulatory region were carried out by Lok et 
al. (2002) and Willingham (2004 ). Lok et al. (2002) cloned 1.3 kb of the 5' promoter and 
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carried out a deletion analysis to determine the boundaries of the minimal promoter. 
Deletion of a region from - 555 to -456, within the 1.3 kb promoter, resulted in a 70% 
decrease in promoter activity, thus identifying this region as containing impo11ant 
transcription factor binding sites . 
Initial computational analysis of the topoisomerase II beta promoter region between -456 
and - 555 identified two inverted CCAAT boxes (ICBs) , which are possible binding sites 
for Nuclear Factor Y ( F-Y), and one GC rich element, which could bind Specificity 
factor I (Sp!) or Specificity factor 3 (Sp3) (Lok et al. , 2002). Magan (2002) also 
identified these putative transcription factor binding sites, as well as the following 
additional putative binding sites in the full length -1357 topoi somerase II beta promoter: 
two Activator Protein 2 sites (AP-2) , an Acti vating Transcription Factor (A TF) site, a 
further GC rich element, and two additional ICB elements (Figure I .4). 
5' 3' 
+I 
-1328 -947 -808 -705 -548 -5 22 -• 90 -2• 5 
Figure 1 .4: Topoisomerase II Beta Promoter. 
Schemati c n:presentation of the putative regulatory elements in th e topo isome rase II be ta promoter re lati ve 
to the maj o r transcripti on start site. + I. Four in verted CCAA T boxes ( IC B), two acti va tor prote in binding 
s ite (AP2 ), an ac ti vating transcripti on fac tor binding site (A TF ) and three GC-ri ch elements (GC) have bee n 
identi lied (Adapted from Lok el al. , 2002; Magan. 2002 ). 
1.5.2. CCAAT Boxes 
The sequence CCAAT or A TTGG (reverse orientation) is defined as a CCAA T box. The 
CCAA T box is found in a large number of promoters, and is one of the most common 
elements in eukaryotic promoters. It can be in either the forward or reverse orientation, 
and in higher eukaryotes, it is found in the reverse orientation approximately 60% of the 
time (Mantovani, 1998). [n promoters containing a TAT A element the CCAA T box can 
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be found in either orientation, and on average it is located between - 80 and - 100 with 
respect to the transcription start site. In TAT A-less promoters, however, the CCAA T box 
is more often in the reverse direction, and it is positioned closer to the transcription start 
site, between -41 and - 80 with respect to the transcription start site (Mantovani , 1998). It 
is thought that both the orientation and location of the CCAA T box in TAT A-less 
promoters may be of importance for the positioning of other transcription factors , and 
subsequently R A polymerase II close to the transcription start site. 
A number of proteins have been shown to bind to CCAA T boxes. CCAAT/enhancer 
binding protein, C/EBP, binds to this element, and has been shown to be an activator of 
transcription (Umek er al., 1991 ). CCAA T transcription fac tor, CTF/NF-1 , recognises the 
sequence TGC(N)6GCCAA (Zorbas er al., 1992), where the T is not strictly required for 
binding. The CCAA T displacement protein was initially found to bind to CCAA T boxes 
in sea urchin and repress the expression of the sperm H2B gene (Barberis et al. , 1987). 
Inverted CCAAT box binding protein 90 kDa ( lCBP90) was first identified as an lC B2 
binding protein in the context of the topoisomerase II a lpha promoter (Hopfner er al., 
2000). These authors showed ICBP90 is highly expressed in proliferating cells , as is 
topoisomerase Il alpha, at both the mRNA and protein level. Over-expression of lCBP90 
leads to an increase in topoisomerase II a lpha expression , which suggests that ICBP90 
may play a role in the regulation of topoisomerase II alpha. By far the most common 
CCAAT box binding protein is uclear Factor Y (NF-Y), and it has been shown to bind 
to this element in a large number of promoters (Mantovani , 1999). F-Y has been shown 
to activate the transcription of a gene through interactions with the chromatin or through 
the recruitment of other proteins to the promoter (Motta et al., 1999; Caretti et al., 2003). 
Many studies have been carried out to gain insight into the regulation of topoisomerase II 
alpha, and detennine the regulatory elements of importance in its promoter. Hochhauser 
et al. ( 1992) first reported the presence of multiple CCAA T boxes in the topoisomerase II 
alpha promoter, and !CB 1 (at position - 68) was subsequently shown to be of particular 
importance for basal expression (Magan, 2002) . Mutations introduced into !CB I resulted 
in a 60- 70% decrease in transcription (Magan et al., 2003). ICB2 is essential for the 
down-regulation of topoisomerase II alpha at confluence-arrest (Isaacs et al., 1996), and 
for cell cycle-regulated expression, specifically the down-regulation at G(0)/G( I) phase 
(Falck et al., I 999). Numerous studies have shown that F-Y is capable of binding to 
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this element, and that this interaction has a role 1n the regulation of topoisomerase [I 
alpha. 
The topoisomerase II beta promoter contains multiple ICBs . !CB I and ICB2 are located 
490 and 522 bases upstream of the transcription start site respectively (Willingham, 2004) 
and are considered to have functional significance. Mutations introduced into either of 
these two [CBs, in the context of the full-len gth promoter, results in a modest 20- 25% 
decrease in transcription relative to the wild type full -length promoter. A double 
[CB I/ICB2 mutation in the promoter however resulted in a significant 70% decrease in 
the tran cription of a reporter gene suggest ing that there is a functional redundancy 
between these two elements (Lok et al. , 2002). Functionally, both elements are important 
for the expression of the topoisomerase II beta gene, poss ibly due to the transcription 
factors that they recruit to the promoter. 
1.5.3. NF-Y 
NF-Y , also known as CBF, CP I, or YEBP, has an absolute requirement for all five bases 
in the pentanucleotide sequence (CCAA T) and mutations introduced into any of these 
bases inhibits NF-Y binding and activity (Graves et al., 1986; Myers et al., 1986). [n 
addition to this CCAA T sequence, the 3' flanking region 1s also considered to be of 
importance for NF-Y binding. Electrophoretic mobility shift competitor assays 
demonstrated that only when 13 bp or more of the 3' flanking sequence were present, in 
conj unction with the CCAAT box, full competition for NF-Y binding was observed 
(Sugiura and Takishima, 2003). These authors also fo und that the correct positioning of 
certain bases within the 3' flanking sequence were also important for stabilising NF-Y 
binding. 
NF-Y is a protein that consists of three subunits: F-YA, NF-YB and F-YC, all of 
which are required for DNA binding. There is a high degree of evolutionary conservation 
of NF-Y, which suggests that NF-Y has a fundamentally important role in the cell. Sinha 
et al. (1995) showed that there was a preci se way in which the NF-Y heterotrimer is 
assembled. First ly, NF-YB and NF-YC form a tight interaction with each other, and this 
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provides the base for NF-YA association. NF-YA binding is weaker than the NF-YB/NF-
YC interaction, and the whole complex is stabilized upon DNA binding. 
NF-Y itself may not have the ability to directly act ivate the transcription of a gene, 
however it may play a role in the structural organization of the DNA. Ronchi et al., 
( 1995) showed that NF-Y fon11S interactions with the minor groove of the D A double 
helix, and that upon DNA binding, introduces a di stortion into the DNA double helix. 
DNA bending assays showed that NF-Y was capable of bending the DNA between 62° 
and 82°. It is possible that this bending may open up the DN A, thereby allowing the 
binding of other transcription factors. In addition, NF-Y has been shown to interact with 
the histone acety ltransferases, P/CAF and GC 5 (CuITie, 1998; Jin and Scotto, 1998). 
Thi s provides evidence for further opening of the chromatin structure upon NF-Y 
binding, making the D A increasingly accessible to the proteins required for the 
formation of the pre-initiation complex. 
NF-Y could a lso play an important ro le in the recruitment of other proteins to the 
promoter. It has been shown that F-Y is responsible for recrniting TFIID to the major 
hi stocompatibility complex (MHC) class II Ea promoter (Frontini et al. , 2002) . In fac t, 
these authors demonstrated that F-Y is able to interact with a number of different T AFs 
in the TFIID protein complex. Variations in the TAF that F-Y binds to could be of 
impo11ance for the assembly of the initiation complex in different core promoter 
architectures (Frontini et al., 2002). To build on these findings Kabe et al. (2005) 
investigated the recruitment of RNA polymerase II to the osteoclast differentiation factor 
(O DF) gene promoter. A small interfering RNA (directed to F-YA) knocked down F-
Y A, thus preventing F-Y associating with the CCAA T box in the ODF promoter. This 
decrease in F-Y binding to the promoter was concomitant with a decrease in R A 
polymerase II binding to the same promoter. 
Experiments were undertaken to detennine if there were any significant differences in 
transcription factor expression in a Chinese hamster cell line that has reduced levels of 
topoisomerase II alpha (Saxena et al. , 2004). Western blot analysis and quantitative real-
time reverse-transcription PCR showed that NF-Y was decreased at both the protein and 
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mRNA level respectively, thus suggesting that F-Y is activating topoisomerase II alpha 
expression. 
In order to investigate the role of F-Y in the context of the topoisomerase II beta 
promoter Lok et al. (2002) used a dominant negative NF-YA mutant in transient 
transfection experiments. These experiments resulted in decreased levels of reporter gene 
activity, relative to no addition of F-Y A mutant. This suggests that NF-Y may work to 
activate topoisomerase II beta transcription . Lok et al. (2002) also carried out 
transfection assays using a mutant !CB I / ICB2 promoter construct, and showed that the 
dominant negative F-Y A mutant had no effect on reporter gene expression. This 
confirmed that the dominant negative mutant of NF-YA was acting specifically though 
the two !CB elements . Over-expression of wild type NF-YA however, was in ufficient to 
increase transcription, which is logical as all three NF-Y subunits are required for DNA 
binding. It is possible that F-Y activates transcription of the topoisomerase II beta gene 
through the recruitment of other transcription factors to the promoter. 
1.5.4. GC-rich Elements 
The GC-rich element has the general consensus sequence of GGGCGG, and this element 
is found in a large number of eukaryotic promoters. GC-rich elements are of particular 
importance in many ubiquitously expressed genes, tissue-specific expression, and in the 
promoter regions of viral genes. They also occur frequently in promoter regions of genes 
involved in developmental patterning and hormonal activation. 
It has been found that in the topoisomerase II alpha promoter a mutation in GC 1 has no 
significant effect on the expression level. However, a mutation in GC2 results in a 50% 
increase in transcription , which suggests that there is a transcription factor that binds to 
the GC2 element that inhibits transcription (Magan et al. , 2003), or that a functional 
synergism may exist between both these GC-rich elements. 
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A mutation in GC I in the topoisomerase II beta promoter shows that thi s element does 
not bind an inhibitory transcription factor, as there was no significant change in reporter 
gene activity (Lok et al. , 2002), however there may be some co-operation between GC I 
and ICB I or ICB2. When GC I is mutated, in conjunction with either of these elements, 
at least a 50% decrease in transcription was observed. Thi s suggests that the transcription 
factors binding at these sites may be able to recruit each other when a mutation is present 
in only one of their binding sites (Zhong et al. , 2000). 
1.5.5. Sp Family of Transcription Factors 
The Specificity protein (Sp) family of transcription factors have been shown to bind to 
DNA, and act through GC-rich or GC-rich like elements to modulate transcription. To 
date, nine members of the Sp family have been identified (namely Sp I - Sp9). The Sp 
family of transcription factors is characterised by a conserved zinc finger DNA binding 
domain , near the C-tenninal end of the prote in, which faci litates binding to the GC-rich 
elements. 
Sp I and Sp3 are the most well characterised members of the family , and have been 
repeatedly shown to play a major role in the transcriptional regulation in a large number 
of genes (Suske, 1999) . Sp2 is poorly characterised but may play a role in cell 
physiology (Moorefield et al., 2004) and Sp4 ex pression is restricted to the brain (Black 
et al. , 1999). Sp5 has been proposed to have a role in patterning in the developing 
embryo (Han·ison et al. , 2000) , while Sp6 may play a role in the development of 
epithelial tissues ( akamura et al., 2004). Sp7 , also known as Osterix, is only expressed 
in osteoblasts, and is a key regulator of bone cell differentiation (Gao et al., 2004). The 
more recently discovered Sp8 and Sp9 have been shown to play a major role in limb 
outgrowth in embryos (Kawakami et al., 2004). 
Sp l and Sp3 are ubiquitously expressed members of the Sp family, and it is therefore 
possible that these two transcription factors play a role in topoisomerase II beta regulation 
through the GC-rich elements located in the promoter. 
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1.5.6. Sp1 
Sp I is a ubiquitously expressed protein, and it is a bona fide transcriptional activator. The 
Spl gene is located on human chromosome 12ql3 (Gaynor et al., 1993) and there are 
several different isofonns of Sp I (Thomas et al., 2005). 
Cloning and characterisation of the Spl promoter showed that it contained a number of 
GC-rich elements (Nicolas et al., 200 I). Transient transfection experiments showed that 
Sp I activated its own expression , i.e. it is autoregulated, while another member of the Sp 
family , Sp3 , is able to repress Sp I activated transcription (Nicolas et al. , 2003). 
Transcriptional regulation of Sp I also involves both NF-Y and E2F (Nicolas et al. , 2003). 
E2F plays a major role in the activation of expression of genes involved in the transition 
from G( I) to S phase in the cell cycle, and therefore provides a link to the cell cycle-
regulated expression of topoisomerase 11 alpha. 
Post-translational modification has an important role in the regulation of Sp I at the 
protein level. Phosphorylation of serine and threonine re idues in the D A binding 
domain of Sp I prevents Sp I binding to the GC-rich element. The phosphorylation state 
of Sp I is dynamic, Casein Kinase I[ has been shown to phosphorylate Sp I , and protein 
phosphatase I (PP I) is thought to dephosphorylate the protein (Annstrong et al. , 1997). 
Black et al. ( 1999) proposed an additional role for phosphorylation in the interaction with 
other transcription factors . Sp I is also subject to O-glycosylation (Han and Kudlow, 
1997) . This modification may provide a link between nutrient availability and cell 
growth. [n low nutrient states, Sp I becomes hypoglycosylated, and this results in Sp 1 
being targeted to the proteasome for degradation (Han and Kudlow, 1997). From these 
results the authors suggested that the subsequent drop in Sp I levels might result in a 
general reduction in transcription, thereby providing a possible mechanism for nutrient 
conservation, as Sp I is involved in the transcriptional activation of many genes. 
Sp I has been fo und to be over-expressed in a large number of cancers such as breast 
cancer (Zannetti et al., 2000), pancreatic cancer (Shi et al. , 200 1) and fibrosarcoma (Lou 
et al., 2005) . Using UlsnRNNribozyrne (which is used to inhibit the expression of a 
specific gene, in this case Sp I) Lou et al. (2005) showed the levels of Sp 1 within the cell 
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decreased and this resulted in a decrease in tumourigenicity, and a decrease in the levels 
of several other proteins involved in malignant transformation. 
Magan et al. (2003) showed that over-expression of Sp I caused a 6-fold increase in 
transcription of a repo11er gene driven by the topoisomerase II alpha promoter, indicating 
that Sp I is a strong activator of topoisomerase II alpha expression. Further evidence 
supporting the role of Sp I as an activator of transcription came from Allen et al. (2004). 
These authors demonstrated that topoisomerase II alpha is down-regulated in breast 
cancer cells exposed to doxorubicin , and that the decrease in topoisomerase II alpha 
expression is concomitant with a decrease in Sp I expression. 
Only one study to date has investigated the role of Sp I on topoisomerase II beta 
expression . Unlike topoisomerase II alpha, this preliminary study found that Sp I had no 
effect on topoisomerase II beta expression (Willingham, 2004) . This result is somewhat 
surprising, as Sp I binds tightly to the GC I element in the topoi somerase II beta promoter 
in vitro (Lok et al., 2002; Willingham, 2004) and acts as a general transcriptional 
activator in a number of different promoters. The role of Sp I in topoisomerase II beta 
regulation will require further investigation. 
1.5.7. Sp-1 and NF-Y Interactions 
NF-Y and Sp I have been shown to co-operate in the regulation of a number of promoters. 
A mutation in the NF-Y binding site is partially compensated by a wild type Sp I binding 
site and vice versa. This was demonstrated by Zhong et al. (2000) when these authors 
were investigating the regulation of the human tissue inhibitor of metalloproteinases-2 
(TIMP-2) gene in response to cyclic AMP (cAMP). No response to cAMP was seen 
when both NF-Y and Spl binding sites were mutated; however, when only one was 
mutated, a partial response was observed. 
Roder et al. ( 1999) wanted to detennine the basis for the co-operation between Sp I and 
NF-Y, which they had previously shown to occur in the fatty acid synthase insulin-
responsive element I promoter (Roder et al., 1997). Using yeast two-hybrid assays, 
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GST-pull-down assays, and co-immunoprecipitation experiments, these authors 
demonstrated conclusively that Sp I and NF-Y physica lly interact both in vivo and in 
vitro . An independent study by Liang et al. (200 I) also demonstrated that Sp I and NF-Y 
could phys ically interact, and that this interaction may be of functional importance in the 
transcriptional regulation of the type A natriuretic peptide receptor ( PR-A) gene. 
The promoter of the MHC Class II-associated in variant chain gene contains an imperfect 
ICB, and a GC-rich element within c lose proximity to each other. F-Y and Sp I were 
shown to bind to their respective elements; however binding of e ither transcription factor 
on its own had no effect on transcription (Wright et al., 1995). Only when both 
transcription factors were present was there a s ignificant increase in transcriptional 
activation by NF-Y and Sp!. It is possible that Spl binding stabilises NF-Y binding to 
the imperfect ICB, and that this interaction makes it possible for NF-Y to recruit the other 
transcription factors required for activating transcription. 
1.5.8. Sp3 
Sp3 , like Sp I , is a ubiquitously expressed protein. Unlike Sp I , however, Sp3 exhibits 
two functions , as either an activator or a repressor of transcription. The Sp3 gene is 
located on human chromosome 2q3 1, and through differential translation initiation sites, 
three different size proteins can be produced; two small 58 - 60 kDa protei ns, and one 
full-length 110 kDa protein (Kennett et al. , 1997) . Kennett et al. (1997) also showed that 
the two smaller proteins had very little trans-activation activity, however they were 
shown to be potent inhibitors of Sp 1- or Sp3-mediated trans-activation. 
Unique to Sp3 is an inhibitor domain that enables it to repress transcription. By preparing 
a series of deletion constructs Dennig et al. ( 1996) narrowed the region responsible for 
the inhibitory function down to a short 13 amino acid sequence, consisting of highly 
charged residues. Further mutational analysis of these amino acids identified the triplet , 
lysine (K), glutamic acid (E), glutamic acid (E), (amino acids 423-425), as the essential 
factor for the inhibition of transcription (Dennig et al., 1996). 
-2 1-
Chapter 1 - Introduction 
Sp3 undergoes a range of post-translational modifications like Sp I. Phosphorylation of 
Sp3 has been shown to increase DNA binding affinity (Ge et al., 2001). [tis thought that 
the lysine (residue 423) located in the inhibitory domain may be important in the switch 
between Sp3 acting as a transcriptional repressor or activator. This residue is subject to 
acetylation (Braun et al., 200 I; Ammanamanchi et al. , 2003) and is also one of the 
essential amino acids in the SUMO (small ubiquitin-like modifier) modification motif 
(IKEE) (Ross et al. , 2002). When acetylated, Sp3 becomes a strong activator of 
transcription (Ammanamanchi et al., 2003), however if this same lysine residue has a 
SUMO moiety added, it becomes a potent repressor of transcription (Ross et al., 2002). 
Both acetylation and SUMO modification are reversible and therefore are 
interchangeable. This suggests that the post-translational modification present on Sp3 
may be a key determinant in its function as either a transcriptional activator or repressor. 
The relative levels of Sp I and Sp3 are thought to be important in the transcriptional 
regulation of a gene. Deluca et al. ( 1996) showed that Sp3 was able to repress Sp I 
mediated activation of a gene by competing for DNA binding. More recently , Williams 
(submitted) used chromatin immunoprecipitation assays to show that Sp I and Sp3 were 
able to compete for binding to the topoisomerase II alpha promoter, and that Sp3 was 
dominant over Sp I and consequently repressed Sp I mediated activation of transcription. 
The role Sp3 plays in the regulation of topoisomerase ll beta remains unknown. It has 
been shown to bind to the GC I element in vitro, and when co-expression reporter gene 
experiments were carried out a modest 20% decrease in topoisomerase ll beta promoter 
activity was observed (Wi llingham, 2004). Further work is required to establish the 
precise role of this transcription factor in topoisomerase II beta regulation, but 
preliminary studies suggest a role in repression. 
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1.6. Project Outline 
To date, very few reports have been published regarding the transcriptional regulation of 
human topoisomerase II beta, while much is known about the mechanisms involved in the 
transcriptional regulation of topoisomerase II alpha. 
It is clear that topoisomerase II alpha and topoisomerase II beta are regulated in different 
ways, even though they both have si milar elements in their promoters. Topoisomerase II 
alpha is cell cycle-regulated, expressed at high levels in proliferating cells, and is the 
specific target of a number of chemotherapeutic drugs. Meanwhile, topoisomerase II beta 
is not cell cycle-regulated, it is ubiquitously expressed amongst a ll tissues , and it too is 
the target of chemotherapeutic drugs. The down-regulation of both of these isoforms of 
topoisomerase II is a major clinical problem as it leads to drug-resistance during 
chemotherapy for a number of cancers. 
Further research into the transcriptional regulation of topoisomerase 11 beta would 
provide a better understanding of the underlying mechanisms involved in the 
development of resistance to drugs targeting this isoform. By investigating which 
proteins bind to the elements in the topoisomerase II beta promoter, and detennining the 
functional effects of these protein-ON A interactions, an understanding of the down-
regulation of this enzyme in drug-resistance may be achieved. 
Research aims: 
I . Detennine the proteins which bind to the ICB I , ICB2, GC l and GC2 element of the 
topoisomerase II beta promoter, using electrophoretic mobility shift assays. 
2 . Investigate the effect of over-expression of Sp 1 and Sp3 on transcription from the 
topoisomerase II beta promoter in reporter gene assays . 
3 . Clone a series of topoisomerase 11 beta promoter constructs containing mutations in 
lCB I , ICB2 and GC I and all combinations of these elements. 
4. Establish the effect these mutations have on the level of transcription generated by 
the topoisomerase II beta promoter, using reporter gene assays. 
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